ALK's (ALKB:DC / Nasdaq Copenhagen: ALK B) full-year results came in at the top end of the latest outlook, supported by solid performance in Q4 and continued commercial momentum. ALK expects sustained high organic revenue growth of 11-15% and higher earnings in 2026, with profitability at around 25%, in line with ALK's long-term targets. The Board of Directors recommends dividend payments for 2025 of DKK 355 million, corresponding to approximately 30% of net profit after tax, to reward shareholders directly ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application for giredestrant, an investigational oral therapy, in combination with everolimus for the treatment of adult patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer follow. ...

Core Viewpoint - Prosafe SE has appointed Halvdan Kielland as the permanent chief financial officer (CFO), highlighting the company's commitment to leadership stability and strategic growth [1][2]. Group 1: Leadership Appointment - Halvdan Kielland joined Prosafe as Corporate Finance Lead in January 2025 and was appointed Interim CFO in November 2025 before being named permanent CFO [1]. - The CEO of Prosafe, Reese McNeel, expressed confidence in Kielland's contributions, particularly in guiding the company through refinancing and positioning for future growth [2]. Group 2: Company Overview - Prosafe is a leading owner and operator of semi-submersible accommodation vessels and is listed on the Oslo Stock Exchange under the ticker code PRS [2].

Core Viewpoint - HIVE Digital Technologies Ltd. has received a recommendation from independent proxy advisory firms, including Institutional Shareholder Services (ISS), to vote "FOR" all resolutions at the upcoming Annual General and Special Meeting of Shareholders on March 5, 2026 [1][3]. Company Overview - HIVE Digital Technologies Ltd. is the first publicly listed company to mine digital assets powered by green energy, operating next-generation data centers across Canada, Sweden, and Paraguay [7]. - The company serves both Bitcoin and high-performance computing clients, providing scalable and environmentally responsible solutions for the digital economy [7]. Shareholder Voting Information - The Board of Directors of HIVE recommends that shareholders vote "FOR" all resolutions [4]. - The proxy voting deadline is set for 11:00 a.m. (Pacific Time) on March 3, 2026, and shareholders are encouraged to vote in advance [5][9]. - Shareholders of record as of January 16, 2026, are eligible to vote at the meeting [5]. Proxy Advisory Firm Details - ISS, an independent proxy advisory firm, has approximately 3,400 clients, including many leading institutional investors who rely on its analysis for voting decisions [2].

Core Viewpoint - Roche's giredestrant, in combination with everolimus, has received FDA acceptance for a New Drug Application aimed at treating advanced ER-positive breast cancer, with a decision expected by December 18, 2026 [1][5]. Group 1: Clinical Efficacy - The phase III evERA Breast Cancer study demonstrated that giredestrant plus everolimus reduced the risk of disease progression or death by 44% in the intention-to-treat (ITT) population and by 62% in the ESR1-mutated population compared to standard-of-care therapy [2][5]. - In the ESR1-mutated population, the median progression-free survival (PFS) was 9.99 months for giredestrant compared to 5.45 months for the comparator arm, while in the ITT population, the median PFS was 8.77 months versus 5.49 months [2][5]. - Overall survival data showed a positive trend in both ITT (HR=0.69) and ESR1-mutated populations (HR=0.62), although data were immature at the time of analysis [2][5]. Group 2: Treatment Context - ER-positive breast cancer accounts for approximately 70% of breast cancer cases, and resistance to endocrine therapies is a significant challenge, particularly after CDK4/6 inhibitor treatment [3][8]. - Giredestrant's oral combination therapy aims to address treatment resistance by targeting different signaling pathways, potentially improving patient quality of life by eliminating the need for injections [3][8]. Group 3: Future Developments - Roche plans to submit additional phase III data from the lidERA study for early-stage breast cancer to health authorities worldwide, including the FDA [3][6]. - The persevERA readout in first-line ER-positive breast cancer is anticipated in the first half of the year, which will further support giredestrant's role in treatment [3][6]. Group 4: Company Commitment - Roche has a comprehensive clinical development program for giredestrant, reflecting its commitment to providing innovative treatments for patients with ER-positive breast cancer across various settings [4][9].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - CDN Maverick Capital Corp. has received an exploration work permit from Québec's Ministère des Ressources Naturelles et des Forêts for diamond drilling on its Nottaway Property, which is located approximately 75 km north-northeast of Matagami, Québec [1][2]. Exploration Permit Details - The Authorization of impact-causing exploration work permit (ATI) was issued on February 16, 2026, and is valid for three years [2]. - The company is prepared to drill high-conductivity electromagnetic conductors that have not been tested previously, with the potential for significant findings in 2026 [2]. Geological Context - The Nottaway Property is considered prospective for volcanogenic massive sulphide (VMS) mineralization within the Opatica Subprovince [3]. - Historical drilling by SOQUEM Inc. in 2015 revealed sulphide-bearing horizons with notable values of zinc, copper, lead, silver, and gold [3]. - A geophysical reinterpretation indicated that several electromagnetic subsurface conductors were not effectively tested, and a Maxwell plate with an estimated conductivity of 500 S/m remains untested [3]. Company Overview - CDN Maverick Capital Corp. is focused on identifying and advancing undervalued mineral assets through disciplined, data-driven investment strategies, particularly in critical minerals and battery metals projects across North America [5].

Core Insights - Ekspress Grupp's revenue continued to grow in Q4 and for the full year 2025, driven by investments in conference business, ticket sales, and digital outdoor screens, alongside strong growth in digital subscriptions [1][9] Revenue Performance - Q4 2025 revenue increased by EUR 0.4 million (+2%) year-over-year, totaling EUR 23.9 million, while the full year revenue rose by EUR 4.1 million (+5%) to EUR 80.2 million [1][8] - The main contributors to revenue growth included the Estonian Training and Conference Centre and UAB Kenton Baltic, along with Delfi Lithuania's AI project and growth in digital subscriptions and ticket sales [1][9] Digital Revenue Growth - Digital revenue for the full year increased by 5%, with nearly 18,000 new digital subscriptions (+7%), reaching a total of 256,000 subscriptions by the end of Q4 2025 [2][11] - Digital revenue accounted for 86% of total revenue at the end of Q4 2025, up from 85% the previous year [11][22] Ticket Sales and Outdoor Screens - Revenue from ticket sales platforms increased by 6% in Q4, while outdoor screen revenue grew by 16%, supported by an expanded network of screens [3][22] Profitability Metrics - Q4 2025 EBITDA totaled EUR 5.3 million, a 1% increase year-over-year, with a margin of 22% [4][13] - Full year EBITDA also increased by 1% to EUR 10.8 million, with a margin of 13% [4][13] Net Profit and Loss - The consolidated net loss for Q4 2025 was EUR 0.9 million, a decrease of EUR 4.0 million from the previous year, while the full year net profit totaled EUR 1.0 million, down by EUR 2.2 million [5][16] - Excluding one-off expenses, the net profit for Q4 was EUR 3.3 million (+6%), and for the full year, it was EUR 3.2 million, approximately the same as last year [5][15][16] Cash Position and Liquidity - As of December 31, 2025, the Group had available cash of EUR 14.0 million, up from EUR 9.0 million the previous year, indicating strong liquidity [7][17] - The Group's net debt decreased to EUR 13.1 million from EUR 19.6 million in the previous year [17] Acquisitions and Strategic Growth - In December 2025, the Group acquired Liikluslab Baltic OÜ, aiming to expand its digital business and enter a new market segment [6]

Core Insights - Roche's New Drug Application for giredestrant has been accepted by the U.S. FDA for treating advanced ER-positive breast cancer, with a decision expected by December 18, 2026 [1][7] - Giredestrant in combination with everolimus has shown significant efficacy in delaying disease progression, with a 44% reduction in risk in the intention-to-treat population and 62% in the ESR1-mutated population [2][7] Company Developments - The acceptance of the filing is based on positive results from the phase III evERA Breast Cancer study, which demonstrated improved progression-free survival (PFS) compared to standard therapies [2][9] - Roche plans to submit additional data from the giredestrant clinical program to other global health authorities, indicating a broad strategy for regulatory approval [4][6] Clinical Study Results - In the ESR1-mutated population, median PFS was 9.99 months for giredestrant plus everolimus versus 5.45 months for the comparator, while in the ITT population, it was 8.77 months versus 5.49 months [2][10] - Overall survival data showed a positive trend, with HR of 0.69 in the ITT population and 0.62 in the ESR1-mutated population, although data were still immature at the time of analysis [3][10] Market Context - ER-positive breast cancer represents approximately 70% of breast cancer cases, and there is a significant need for effective treatments due to resistance to existing endocrine therapies [5][13] - Giredestrant's oral formulation aims to provide a less invasive treatment option, potentially improving patient adherence and quality of life [5][11] Future Outlook - Roche's extensive clinical development program for giredestrant includes multiple phase III trials across various treatment settings, reinforcing its commitment to addressing the needs of patients with ER-positive breast cancer [12][15] - Upcoming data from the lidERA trial and the persevERA readout are expected to further support giredestrant's role in the treatment landscape for ER-positive breast cancer [6][12]

Core Insights - dsm-firmenich published its Integrated Annual Report (IAR) for 2025, highlighting its innovation-led growth agenda and strategic advancements [1] - The report provides a comprehensive overview of the company's financial and non-financial progress, focusing on becoming a fully consumer-focused entity in nutrition, health, and beauty [2] Financial Performance - The IAR details the Group's performance and the delivery of synergies aimed at creating sustainable long-term value for stakeholders [2] Business Units and Innovations - Each Business Unit's breakthrough innovations are reviewed, including the recent divestment of the Animal Health & Nutrition business [3] Sustainability Efforts - The report emphasizes the company's positive impact on climate, nutrition, health, and people, with sustainability statements aligned with European Sustainability Reporting Standards [3] Accessibility of the Report - The 2025 IAR is available on a dedicated website, including a downloadable version in ESEF format as per European Commission regulations [4] Company Overview - dsm-firmenich operates in nearly 60 countries, generating revenues exceeding €12 billion, and employs around 30,000 people [5]